Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Genetic and pharmacologic studies in mice support this framework, although receptor specificity and downstream signaling remain areas of active investigation
Semaglutide (Wegovy) GLP-1 Receptor Agonist Administration : Once-weekly subcutaneous injection OR once-daily oral tablet
Research has shown that oral glutathione supplementation (in reduced or liposomal form) can support skin clarity and tone, especially in individuals with oxidative stress or pigmentation concerns
Hypoglycemia (low blood sugar) dizziness or light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability or mood changes, confusion or drowsiness, fast heartbeat, feeling jittery
